Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.

Leivers AL, Tallant M, Shotwell JB, Dickerson S, Leivers MR, McDonald OB, Gobel J, Creech KL, Strum SL, Mathis A, Rogers S, Moore CB, Botyanszki J.

J Med Chem. 2014 Mar 13;57(5):2091-106. doi: 10.1021/jm400781h. Epub 2013 Aug 14.

PMID:
23944386
2.

Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.

Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, Abrignani S, Neddermann P, De Francesco R.

PLoS Pathog. 2012;8(3):e1002576. doi: 10.1371/journal.ppat.1002576. Epub 2012 Mar 8.

3.

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.

Reiss S, Harak C, Romero-Brey I, Radujkovic D, Klein R, Ruggieri A, Rebhan I, Bartenschlager R, Lohmann V.

PLoS Pathog. 2013 May;9(5):e1003359. doi: 10.1371/journal.ppat.1003359. Epub 2013 May 9.

4.

NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.

Reghellin V, Donnici L, Fenu S, Berno V, Calabrese V, Pagani M, Abrignani S, Peri F, De Francesco R, Neddermann P.

Antimicrob Agents Chemother. 2014 Dec;58(12):7128-40. doi: 10.1128/AAC.03293-14. Epub 2014 Sep 15.

5.

Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.

Harak C, Radujkovic D, Taveneau C, Reiss S, Klein R, Bressanelli S, Lohmann V.

J Virol. 2014 Sep 1;88(17):9909-26. doi: 10.1128/JVI.01063-14. Epub 2014 Jun 11.

6.

Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.

Lim YS, Hwang SB.

J Biol Chem. 2011 Apr 1;286(13):11290-8. doi: 10.1074/jbc.M110.194472. Epub 2011 Feb 5.

7.

Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.

Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G.

J Virol. 2012 Nov;86(21):11595-607. doi: 10.1128/JVI.01320-12. Epub 2012 Aug 15.

8.

Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.

Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R.

Cell Host Microbe. 2011 Jan 20;9(1):32-45. doi: 10.1016/j.chom.2010.12.002.

10.

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR 2nd, Colonno RJ, Gao M, Meanwell NA, Hamann LG.

J Med Chem. 2014 Mar 13;57(5):2013-32. doi: 10.1021/jm401836p. Epub 2014 Feb 12.

PMID:
24521299
11.

Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.

Maynard A, Crosby RM, Ellis B, Hamatake R, Hong Z, Johns BA, Kahler KM, Koble C, Leivers A, Leivers MR, Mathis A, Peat AJ, Pouliot JJ, Roberts CD, Samano V, Schmidt RM, Smith GK, Spaltenstein A, Stewart EL, Thommes P, Turner EM, Voitenleitner C, Walker JT, Waitt G, Weatherhead J, Weaver K, Williams S, Wright L, Xiong ZZ, Haigh D, Shotwell JB.

J Med Chem. 2014 Mar 13;57(5):1902-13. doi: 10.1021/jm400317w. Epub 2013 May 29.

PMID:
23672667
12.

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.

Chukkapalli V, Berger KL, Kelly SM, Thomas M, Deiters A, Randall G.

Virology. 2015 Feb;476:168-79. doi: 10.1016/j.virol.2014.12.018. Epub 2014 Dec 26.

13.

Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.

Munakata T, Inada M, Tokunaga Y, Wakita T, Kohara M, Nomoto A.

Antiviral Res. 2014 Aug;108:79-87. doi: 10.1016/j.antiviral.2014.05.011. Epub 2014 Jun 2.

PMID:
24893207
14.

Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2.

Khan I, Katikaneni DS, Han Q, Sanchez-Felipe L, Hanada K, Ambrose RL, Mackenzie JM, Konan KV.

J Virol. 2014 Nov;88(21):12276-95. doi: 10.1128/JVI.00970-14. Epub 2014 Aug 13.

15.

Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening.

Trotard M, Lepère-Douard C, Régeard M, Piquet-Pellorce C, Lavillette D, Cosset FL, Gripon P, Le Seyec J.

FASEB J. 2009 Nov;23(11):3780-9. doi: 10.1096/fj.09-131920. Epub 2009 Jul 16.

PMID:
19608626
16.

Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.

Lee C.

Arch Pharm Res. 2011 Sep;34(9):1403-7. doi: 10.1007/s12272-011-0921-6. Review.

PMID:
21975800
17.

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA.

Antimicrob Agents Chemother. 2015 May;59(5):2496-507. doi: 10.1128/AAC.04958-14. Epub 2015 Feb 9.

18.

Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking.

Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, Tai AW.

Gastroenterology. 2014 May;146(5):1373-85.e1-11. doi: 10.1053/j.gastro.2014.02.002. Epub 2014 Feb 8.

19.

Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.

Xu S, Pei R, Guo M, Han Q, Lai J, Wang Y, Wu C, Zhou Y, Lu M, Chen X.

J Virol. 2012 Dec;86(23):13025-37. doi: 10.1128/JVI.01785-12. Epub 2012 Sep 26.

20.

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.

Belema M, Nguyen VN, Romine JL, St Laurent DR, Lopez OD, Goodrich JT, Nower PT, O'Boyle DR 2nd, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang YK, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB.

J Med Chem. 2014 Mar 13;57(5):1995-2012. doi: 10.1021/jm4016203. Epub 2014 Jan 17.

PMID:
24437689

Supplemental Content

Support Center